STOCK TITAN

NUS Insider Notice: 6,489 Class A Shares to Be Sold via William Blair

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

NuSkin Enterprises, Inc. (NUS) Form 144 shows a proposed sale of 6,489 Class A shares through William Blair in Chicago, to be executed approximately on 09/04/2025 on the NYSE. The filing lists an aggregate market value of $77,868.00 and reports 49,497,715 Class A shares outstanding for the issuer.

The 6,489 shares were acquired from the issuer as compensation across annual grant dates: 04/30/2021 (422 shares), 04/30/2022 (2,467), 04/30/2023 (3,179) and 04/30/2024 (421), with matching payment dates. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material adverse information.

Positive

  • Full disclosure of planned sale including broker, share count, aggregate market value, planned sale date, and exchange
  • Acquisition history provided showing the shares were received as compensation with specific dates and amounts
  • No securities sold in the past three months, reducing concerns about immediate prior insider selling activity

Negative

  • None.

Insights

TL;DR: A routine disclosure of an insider sale of compensated shares through a broker; no recent sales reported.

The filing documents a small, planned sale of 6,489 Class A shares acquired as compensation over 2021–2024 and routed through William Blair. The disclosure includes aggregate market value and outstanding share count, enabling transparency of the proposed sale. The absence of sales in the prior three months and the representation regarding material nonpublic information suggest this is a routine liquidity event rather than a reaction to new company-specific developments.

TL;DR: Form 144 appears complete for Rule 144 notice purposes and contains the required attestations.

The document lists acquisition dates, nature of acquisition (compensation), payment dates, broker details, planned sale date, and market value; it also includes the mandatory signature attestation concerning material information. From a compliance standpoint the form contains the core elements required for a proposed Rule 144 sale notice and notes no aggregated sales in the recent three-month window.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What Class A securities is NUS proposing to sell in this Form 144?

The filing proposes the sale of 6,489 Class A shares of NuSkin Enterprises.

When is the proposed sale date and through which broker will the NUS shares be sold?

The approximate sale date is 09/04/2025 and the broker listed is William Blair (150 N Riverside Plaza, Chicago, IL).

What is the aggregate market value and how many Class A shares are outstanding for NUS?

The aggregate market value is reported as $77,868.00 and the filing lists 49,497,715 Class A shares outstanding.

How were the 6,489 shares acquired according to the Form 144?

All shares were acquired from the issuer as compensation on the dates 04/30/2021, 04/30/2022, 04/30/2023, and 04/30/2024.

Did the filer sell any NUS securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.
Nu Skin Enter

NYSE:NUS

NUS Rankings

NUS Latest News

NUS Latest SEC Filings

NUS Stock Data

489.94M
46.43M
2.16%
74.97%
3.89%
Household & Personal Products
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
PROVO